Compare WKHS & MAIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WKHS | MAIA |
|---|---|---|
| Founded | 2007 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Auto Manufacturing | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 17.4M | 44.9M |
| IPO Year | N/A | 2022 |
| Metric | WKHS | MAIA |
|---|---|---|
| Price | $5.56 | $1.46 |
| Analyst Decision | Hold | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $21.00 | N/A |
| AVG Volume (30 Days) | 379.0K | ★ 994.9K |
| Earning Date | 11-10-2025 | 11-07-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $10,620,296.00 | N/A |
| Revenue This Year | $92.70 | N/A |
| Revenue Next Year | $34.00 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 16.73 | N/A |
| 52 Week Low | $5.10 | $0.87 |
| 52 Week High | $139.70 | $2.74 |
| Indicator | WKHS | MAIA |
|---|---|---|
| Relative Strength Index (RSI) | 67.28 | 60.20 |
| Support Level | $5.10 | $1.13 |
| Resistance Level | $6.00 | $1.75 |
| Average True Range (ATR) | 0.89 | 0.15 |
| MACD | -0.04 | 0.02 |
| Stochastic Oscillator | 43.43 | 53.23 |
Workhorse Group Inc is a technology company with a vision to pioneer the transition to zero-emission commercial vehicles. Its focus is to provide sustainable and cost-effective solutions to the commercial transportation sector. It designs and manufactures all-electric delivery trucks and drone systems, including the technology that optimizes the way these vehicles operate. It's focused on a core competency of bringing electric delivery vehicle platforms to serve the last-mile delivery market. Its products are marketed under the Workhorse brand.
MAIA Biotechnology Inc is a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer. THIO (6-thio-dG or 6-thio-2 '-deoxyguanosine), its lead asset, is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. Patients with advanced NSCLC will be treated first with THIO followed a few days later by the immune checkpoint inhibitor Libtayo (cemiplimab), manufactured and commercialized by Regeneron.